Oculus Innovative Sciences Announces Fiscal Third Quarter 2016 Financial Results and Conference Call
21 janv. 2016 04h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (tradable warrants OCLSW) today announced that the financial results for its fiscal third quarter...
Oculus Innovative Sciences Receives European CE Mark for New MucoClyns™ for First Responders
14 janv. 2016 04h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), warrants OCLSW, a specialty pharmaceutical company that develops and markets solutions for...
Oculus Innovative Sciences Receives FDA Clearance for Microcyn®-Based SebDerm Gel
17 déc. 2015 04h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the...
Oculus Innovative Sciences Announces Fiscal Second Quarter 2016 Financial Results and Conference Call
22 oct. 2015 06h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradable warrants (NASDAQ:OCLSW) today announced that the financial results for its fiscal...
Oculus Innovative Sciences Introduces MicrocynAH(R) Next-Generation Dermatology Products With Dimethicone for Animals
24 sept. 2015 06h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (tradable warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions...
Oculus Innovative Sciences Announces Preliminary Results for Its 2015 Annual Meeting of Stockholders
11 sept. 2015 18h30 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Sept. 11, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradeable warrants (NASDAQ:OCLSW) today announced that the four proposals presented in its annual...
Oculus Innovative Sciences Announces Introduction of Alevicyn SG Antipruritic Spray Gel for Relief of Pain and Itch in Atopic Dermatitis
19 août 2015 06h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of...
Oculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016
30 juil. 2015 16h05 HE
|
Sonoma Pharmaceuticals, Inc.
U.S. dermatology and Latin American sales drive 37% product revenue growth
FDA 510k clearance for treatment of atopic dermatitis with a unique "no touch" spray gel
Cash as of June 30,...
Oculus Innovative Sciences Announces Fiscal First Quarter 2016 Financial Results and Conference Call
16 juil. 2015 06h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 16, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal first quarter 2016, ended June 30, 2015,...
Oculus Innovative Sciences Receives New U.S. Patent for Microcyn(R) Technology in Treatment of Atopic Dermatitis
08 juil. 2015 06h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 8, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of...